Sudden cardiac death: Implantable cardioverter defibrillators and pharmacological treatments

Critical Care Nursing Quarterly

Volumn 26, Issue 1, 2003, Pages 45-49

  Zhang, Joan ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cardiomyopathy; Implantable cardioverter defibrillator; Sudden cardiac death; Ventricular fibrillation; Ventricular tachycardia

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; METOPROLOL; SPIRONOLACTONE;

ARTICLE; CARDIOMYOPATHY; CAUSE OF DEATH; CLINICAL TRIAL; DEFIBRILLATOR; DRUG EFFECT; HEART FAILURE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTHYROIDISM; LUNG TOXICITY; RISK FACTOR; SUDDEN DEATH;

EID: 0037232288     PISSN: 08879303     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002727-200301000-00008     Document Type: Article

References (13)

1. Myerburg RJ. Sudden cardiac death: exploring the limits of our knowledge. J Cardiovasc Electrophysiol. 2001;12:369-381.
2. American Heart Association. 2001 Heart and Stroke Statistical Update. Texas: American Heart Association; 2000.
3. Stevenson WG, Stevenson LW, Middlekauff HR, et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol. 1996;28:1458.
4. Francis GS. Development of arrhythmias in patients with congestive heart failure: pathyphysiology, prevalence and prognosis. Am J Cardiol. 1986;57:3b.
5. Narang R, Cleland JG, Erhardt L, et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J. 1996;17:1390.
6. MERIT-HF study group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERit-HF). Lancet. 1999;353:2001-2007.
7. Uretsky BF, Sheahan RG. Primary prevention of sudden cardiac death in heart failure: will the solution be shocking? J Am Coll Cardiol. 1997;30:1589-1597.
8. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-533.
9. Pitt B, Zannad F, Remme WJ, et al. For the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709.
10. The Antiarrhythmics Versus Implantable Defibrillators (AVID) investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576-1583.
11. Moss A, Hall WJ, Canom DS, et al. For the Multicenter Automatic Defibrillator Implantation Trial (MADIT) investigators. Improved survival with implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933-1940.
12. Moss AJ, Zabera W, Hall WJ, et al. For the Multicenter Automatic Defibrillator Implantation Trial II investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:833-877.
13. Buxton AE, Lee KL, Fisher JD, et al. For the Multicenter UnSustained Tachycardia Trial (MUSTT) investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med. 1999;341:1882-1890.